{'fraction_non_alphanumeric': 0.02939068100358423, 'fraction_numerical': 0.01863799283154122, 'mean_word_length': 5.316742081447964, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes

Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell cycle and gene profile. MDA-MB231 cells showed more sensitivity to imatinib mesylate than to dipyridamole, with an IC50 value of 348 g/mL versus 494 g/mL for imatinib mesylate and dipyridamole, respectively (P-value < 0.05). The up/downregulation of Bax and Bcl2 and metastasis contributing gene (MMP-1) assured the anticancer activity. Also, the apoptotic potential of dipyridamole and imatinib mesylate was verified by arresting cells in the G2/M phase and increasing the percentage of the apoptotic cells in the pre-G1 phase. The antioxidant levels were drug dependent, as they were significantly higher(P<0.05) in cells treated with imatinib than in cells treated with Dipyridamole. Conclusion: Imatinib mesylate growth-inhibitory impact on breast cell lines, either alone or in combination with dipyridamole, may be mediated through up/downregulation of the Bax, Bcl-2, and MMP-1 genes. Imatinib is a promising treatment for breast cancer patients who require targeted therapy.